IMVT vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

IMVT

54.3
AI Score
VS
IMVT Wins

MRNA

35.1
AI Score

Investment Advisor Scores

IMVT

54score
Recommendation
BUY

MRNA

35score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric IMVT MRNA Winner
Forward P/E 0 23.0415 Tie
PEG Ratio 0 0 Tie
Revenue Growth 0.0% 2.1% MRNA
Earnings Growth 0.0% -85.1% IMVT
Tradestie Score 54.3/100 35.1/100 IMVT
Profit Margin 0.0% -141.4% IMVT
Beta 1.00 1.00 Tie
AI Recommendation BUY EXTENDED IMVT

Relative Price Performance (Last 90 Days)

IMVT 1M: -23.9% · 3M: -27.9% MRNA 1M: +34.6% · 3M: +331.1%

Current Technical Phase

IMVT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -8.6%), weak momentum, RSI 29

RSI (14): 28.8 · Price: $28.38

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (58.0% over 20 days), RSI 69

RSI (14): 69.1 · Price: $245.81

Fundamentals Snapshot

Metric IMVT MRNA
Market Cap — —
Forward P/E -11.0 -51.1
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — -0.7%
Operating Margin 0.0% -5.6%
EPS -2.82 -7.98
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, IMVT is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.